Navigation Links
Treatment for deadly yeast disease reduced to 3 days
Date:4/24/2014

Initial treatment for a brain infection caused by fungus could now be treated in three days, rather than two weeks, due to study by University of Liverpool scientists.

Cryptococcus a form of yeast - infections are often fatal but are relatively neglected in medical research. They are found in many parts of the world, including Africa, Australasia and South East Asia and mainly affect people with weakened immune systems. This infection kills up to 700,000 people a year.

The University research team has tested the effects of the most commonly used drug on Cryptococcus infections of the brain and discovered that although the recommendation for treatment is currently two weeks, the drug has been shown by the new studies to be effective at clearing the fungus within three days.

Professor of Therapeutics and Infectious Diseases, William Hope said: "This infection kills up to 700,000 people a year and is mainly fatal in areas with poor resources. In many parts of the world it is simply infeasible to administer intravenous drugs for two weeks."

The scientists in the Institute of Translational Medicine examined the effects of amphotericin B deoxycholate (dAmB) over both three and 14 day treatments and found that the effect was the same after three days as it was after two weeks.

The results in animal trials was compared with humans using a range of mathematical modelling techniques, to produce findings which suggest that the three day regime will be equally as effective in people.

The researchers believe that this opens up significant possibilities for treatment in areas where there is a scarcity of medically trained staff, who often have to ration the drugs they administer to patients.

The infection often takes hold in people with AIDS as a result of their immune systems being compromised, and areas with high rates of AIDS are also usually those without resources.

Professor Hope a
'/>"/>

Contact: Jamie Brown
jamie.brown@liverpool.ac.uk
44-151-794-2248
University of Liverpool
Source:Eurekalert

Page: 1 2

Related biology news :

1. Breakthroughs in Chikungunya research from A*STAR spell new hope for better treatment and protection
2. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
3. Genetic research develops tools for studying diseases, improving regenerative treatment
4. Step forward in research into new treatments for brain edema
5. Marshall University study may lead to new treatments for prostate cancer
6. New discoveries about brain-hand connection sought to improve therapies, treatments, prosthetics
7. Minimally invasive treatment for ruptured aneurysm: Safe, reduces mortality
8. Penn research points to new way of preserving fertility for boys undergoing cancer treatment
9. Researcher who identifed genetic cause and possible treatment for Marfan syndrome honored
10. New discovery may lead to effective prevention and treatment of graft-versus-host dsease
11. Antipsychotic drug may be helpful treatment for anorexia nervosa
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
(Date:3/31/2015)... 31, 2015   Guidepoint , a leading global ... Post-Surgical Pain Management TRACKER, part of the Guidepoint ... in the medical device and therapeutics markets. The Post-Surgical ... treatment volumes, market share, and adoption rates across three ... joint surgery. The Post-Surgical Pain Management TRACKER ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... New research from the University of Michigan Comprehensive ... protein that fuels an inflammatory pathway does not turn ... cancer stem cells. This provides a potential target for ... of the disease. The researchers identified a protein, ...
... glioblastoma cancers so difficult to treat is that malignant cells ... fibers and blood vessels to invade new locations. Now, researchers ... the cancer by using a film of nanofibers thinner than ... of invading new areas, the migrating cells latch onto the ...
... life on earth, is also its least explored environment. ... the ocean,s deep regions, exploiting the deep,s resources and ... for the planet at risk. Lisa Levin, a ... San Diego, believes the vital functions provided by the ...
Cached Biology News:New finding points to potential options for attacking stem cells in triple-negative breast cancer 2Researchers hijack cancer migration mechanism to 'move' brain tumors 2Researchers hijack cancer migration mechanism to 'move' brain tumors 3Researchers hijack cancer migration mechanism to 'move' brain tumors 4Scientists call for new stewardship of the deep ocean: Earth's last frontier 2Scientists call for new stewardship of the deep ocean: Earth's last frontier 3
(Date:4/16/2015)... ROCKVILLE, Md. , April 16, 2015 /PRNewswire/ ... "RegeneRx") today announced its U.S. joint venture with ... conduct a phase 3 clinical trial for the ... dose-response, confirmatory trial for dry eye syndrome (DES) ... ReGenTree,s preservative-free eye drops, RGN-259/GBT201, this year.  Each ...
(Date:4/16/2015)... 16, 2015 ChemRar ... investment and R&D group, and Lancet, Russian ... development and commercialization of new medicines in ... intention to stimulate the innovative development of ... (Logo: http://photos.prnewswire.com/prnh/20150416/739742-a) ,     (Logo: http://photos.prnewswire.com/prnh/20150416/739742-b) , ...
(Date:4/16/2015)... , April 16, 2015  AnaptysBio, Inc., ... of therapeutic antibodies, today announced the advancement ... program into IND-enabling studies. The Company,s anti-IL-36R ... treatment for generalized pustular psoriasis (GPP), an ... medical need. ANB019 is wholly owned within AnaptysBio,s ...
(Date:4/16/2015)... April 16, 2015 Avelas Biosciences, an ... cancer surgeries, announced today that it has initiated a ... AVB-620, in women with primary, non-recurrent breast cancer undergoing ... welcomed the addition of Steven Chen , M.D., ... open label, dose escalation study will enroll up to ...
Breaking Biology Technology:RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3
... 2011   Elsevier, the leading ... will present awards to outstanding members of the wilderness medicine ... Wilderness Medicine Scientific Conference & Annual Meeting , taking place ... rd . The aim of the Wilderness Medicine ...
... Switzerland and RALEIGH, North Carolina, July 26, 2011 ... a therapeutically focused contract research organisation (CRO) with ... Debiopharm Group™ ("Debiopharm"), a Swiss-based global biopharmaceutical group ... diagnostics, today announced a strategic partnership. Under the ...
... 25, 2011 Rising star Divine Skin Inc. (DSKX), which ... Robin Powell, a long-time leader in the cosmetics industry, to ... of retirement by Divine Skin because I believe their innovative ... give proven results with a ,wow, factor." ...
Cached Biology Technology:Elsevier Collaborates with the Wilderness Medicine Society to Award Outstanding Members 2Elsevier Collaborates with the Wilderness Medicine Society to Award Outstanding Members 3INC Research and Debiopharm Group(TM) Announce Strategic Partnership 2INC Research and Debiopharm Group(TM) Announce Strategic Partnership 3Robin Powell Becomes President at Biotech Leader Divine Skin (DSKX) 2
Sprague-Dawley rats, 7-8 weeks old, mixed gender; tissue is collected fresh, frozen on dry ice within minutes of sacrifice and stored at -20C; individual tissue weight approx. 0.05 gram....
Contains L-glutamine...
MMP-20 Immunogen: Activated recombinant human MMP-2 Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-Rsk2/MAPKAP Kinase 1b, #0 SK2/MAPKAP K1 beta Smartpool&t 3T3 cell lysate Non-specific Control Pool , #D 1X Universal Buffer...
Biology Products: